Category: Press Release

Download PDF BOSTON–(BUSINESS WIRE)–Oct. 19, 2020– AVEO Oncology (Nasdaq: AVEO) today announced the appointment of David Crist as Vice President of Sales. In this role, Mr. Crist will be responsible for building out AVEO’s sales force in anticipation of the potential approval and launch of tivozanib, the Company’s next-generation vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), as a treatment

Download PDF BOSTON–(BUSINESS WIRE)–Sep. 15, 2020– AVEO Oncology (Nasdaq: AVEO) today announced that final overall survival (OS) results from its Phase 3 TIVO-3 study were published in the journal European Urology. TIVO-3 is the Company’s pivotal Phase 3 trial comparing tivozanib, AVEO’s next-generation vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor (TKI) drug candidate, to sorafenib in third

Download PDF Announces Decision to Fund Clinical Manufacture of Ficlatuzumab for Potential Phase 3 Study and Update to Biodesix Partnership  No Change to AVEO Cash Runway Guidance BOSTON–(BUSINESS WIRE)–Sep. 8, 2020– AVEO Oncology (Nasdaq: AVEO) today announced that it has regained full global rights to ficlatuzumab, AVEO’s potent hepatocyte growth factor (HGF) inhibitory antibody which binds to the

Download PDF BOSTON–(BUSINESS WIRE)–Sep. 3, 2020– AVEO Oncology (Nasdaq: AVEO) todayannounced that Michael Bailey, president and chief executive officer of AVEO, will participate in two upcoming virtual investor conferences: Baird 2020 Global Healthcare ConferenceDate: Thursday, September 10Time: 8:30 AM Eastern Time H.C. Wainwright 22nd Annual Global Investment ConferenceDate: Monday, September 14Time: 4:30 PM Eastern Time A live webcast of the events can be accessed by

Download PDF – NDA Filing Accepted by U.S. FDA for Tivozanib as a Treatment of Relapsed or Refractory Renal Cell Carcinoma; Assigned PDUFA Target Action Date of March 31, 2021 – – Preparations Underway to Support Potential Commercial Launch of Tivozanib in the U.S.; New Debt and Equity Financings, Partnership Milestones Potentially Provide for Working Capital into 2022 – –

Download PDF BOSTON–(BUSINESS WIRE)–Aug. 10, 2020– AVEO Oncology (Nasdaq: AVEO) today announced the closing of a tranched, $35 million debt facility with Hercules Capital, Inc. (NYSE: HTGC) and its affiliates. The new facility has a maturity of 36 months, extendable up to 48 months, and an interest-only period of 12 months, extendable up to 30 months upon the achievement of performance

Download PDF BOSTON–(BUSINESS WIRE)–Aug. 5, 2020– AVEO Oncology (Nasdaq: AVEO) today announced that it has earned a $2.8 million development milestone payment from partner Kyowa Kirin Co., Ltd. (Kyowa Kirin). The milestone relates to acceptance by the Japanese Pharmaceuticals and Medical Devices Agency of an investigational new drug (IND) application for tivozanib in a non-oncology indication being developed by Kyowa Kirin. “This milestone

Download PDF BOSTON–(BUSINESS WIRE)–Jun. 19, 2020– AVEO Oncology (Nasdaq: AVEO) today announced the closing of its previously announced underwritten public offering of 9,725,000 shares of its common stock, which includes the partial exercise by the underwriters of their option to purchase an additional 1,225,000 shares, at a price to the public of $5.25 per share. The aggregate gross proceeds

Download PDF BOSTON–(BUSINESS WIRE)–Jun. 16, 2020– AVEO Oncology (Nasdaq: AVEO) today announced that it has priced its previously announced underwritten public offering of 8,500,000 shares of its common stock at a price to the public of $5.25 per share. The gross proceeds to AVEO from the offering are expected to be approximately $44.6 million before deducting underwriting discounts and commissions and

Download PDF BOSTON–(BUSINESS WIRE)–Jun. 15, 2020– AVEO Oncology (Nasdaq: AVEO) today announced that it has commenced an underwritten public offering of $40.0 million of shares of its common stock. In connection with the offering, AVEO intends to grant the underwriters a 30-day option to purchase up to an additional $6.0 million of shares of its common stock. All of the shares